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ABSTRACT 
Objective: Investigation of in vitro/in vivo behaviour of fast-dissolving tablets containing solid dispersions of oxcarbazepine is the focus of the 
present research work.  
Methods: The effect of various hydrophilic polymers on the aqueous solubility of oxcarbazepine was studied. Polyethylene glycol 6000 carrier was 
selected and solid dispersions were prepared by various methods. A total of nine formulations were compressed into fast-dissolving tablets using 
avicel PH 102 as a directly compressible filler and ac-di-sol, sodium starch glycolate and crospovidone as super disintegrants and evaluated for pre 
and post compression parameters and in vitro drug release. In vivo studies of the pure drug, optimized formulation and marketed formulation were 
carried out on male Wistar rats and pharmacokinetic parameters were calculated using the pk function for Microsoft excel.  
Results: Mathematical analysis of in vitro data suggested that the first order was the most suitable mathematical model for describing the optimized 
formulation. The first-order plot was found to be fairly linear for optimized formulation as indicated by its high regression value. Stability studies 
indicated that the effect of storage was insignificant at 5% level of confidence. The optimized formulation has shown Tmax of 0.5 h, which was highly 
significant (P<0.05) when compared with pure drug and marketed formulation.  
Conclusion: Therefore, the solid dispersions prepared by melting method using polyethylene glycol 6000 as hydrophilic carrier can be successfully 
used for the improvement of dissolution of oxcarbazepine and resulted in faster onset of action as indicated by in vitro and in vivo studies. 
Keywords: Dissolution profile, Hydrophilic carrier, Melting method, Solubility, Solid dispersion 
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INTRODUCTION 
Oxcarbazepine is an antiepileptic and mood stabilizing drug, used 
primarily in the treatment of epilepsy and bipolar disorder. 
Oxcarbazepine is 10, 11–dihydro-10–oxo-5H-dibenz (b, f) azepine-5-
carboxamide, [1] structural derivative of carbamazepine, [2] adding 
extra oxygen to dibenzepine ring.  
Oxcarbazepine is rapidly and completely absorbed after oral 
administration with negligible first-pass metabolism (absolute 
bioavailability is 98%). The common oral dosage is 150 mg/d 
(dose/solubility ratio ≥250 ml; class II drug according to the BCS). Peak 
plasma concentrations occur anywhere from 1 to 2 h following drug 
administration. This delay in the onset of action in spite of good 
bioavailability is because of its low aqueous solubility which is only 0.30 
g/l. This may result in the delayed onset of action because of sub-
therapeutic plasma drug levels and may also lead to therapeutic failure. 
Hence there is an urgent need to increase the aqueous solubility of 
the drug. Solid dispersions [3, 4] refer to a system in which 
hydrophobic drug is dispersed in a hydrophilic matrix, in order to 
improve its dissolution properties and bioavailability. In solid 
dispersion, a drug can exist in an amorphous or crystalline form in 
hydrophilic polymeric carriers [5, 6] such as polyethylene glycols, 
polyvinyl pyrrolidone K30 and urea etc. which results in improved 
solubility and dissolution rates. 
The objective of the present research work was to formulate fast 
dissolving tablet of oxcarbazepine using a solid dispersion method in 
order to improve its aqueous solubility.  
For this two hydrophilic carriers were evaluated to determine their 
effect on the solubility of oxcarbazepine; different methods were 
then evaluated to select the best method of preparation of solid 
dispersions and the solid dispersion was formulated into fast-
dissolving tablets and effect of formulation on the Tmax of 
oxcarbazepine was studied.  
Oxcarbazepine is having low solubility many techniques have been 
tried in the past in order to improve its solubility and dissolution. 
According to the method developed by the authors in the above text 
direct compression was used for the preparation of fast dissolving 
tablets which is superior to wet granulation technique used earlier 
due to convenience in processing and three different methods 
evaluated for the formulation of solid dispersions as compared to 
previously reported works. According to previously reported 
literature superdisintegrant method used in the above text was 
found to be superior to the other methods of improving the 
dissolution of poorly soluble drugs. 
MATERIALS AND METHODS 
Materials  
Oxcarbazepine was a gift sample from Jubiliant Organosis Ltd (U. P, 
India) and polyethylene glycol 6000, polyethylene glycol 4000 and 
polyvinyl pyrrolidone K30 were purchased from Oxford laboratory 
(Mumbai, India). All other chemicals and reagents used were of 
analytical grade. In order to conduct in vivo studies the institutional 
animal ethical clearance (vide letter no. CPCSEA/MRCP/1217/2008/) 
was obtained before conducting the studies. The results obtained were 
analyzed for various non-compartmental pharmacokinetic parameters 
using pk functions of Microsoft excel. Furthermore, the pharmacokinetic 
data were analyzed statistically [7] by one way ANOVA (P<0.05) 
followed by Dunnett post hoc test for multiple comparisons. 
Screening of appropriate carrier for oxcarbazepine solid 
dispersion using solubility studies 
Solubility measurements were performed according to the method 
reported by Higuchi and Connors [8]. Both polyethylene glycol 4000 
and polyethylene glycol 6000 were assessed for solubility 
enhancement. Various (1%, 2%, 5% and 10% w/v) aqueous 
solutions of polyethylene glycol 4000 and polyethylene glycol 6000 
were prepared and transferred to volumetric flasks. An excess 
amount of drug was added to each flask. The contents of each flask 
(10 ml) were equilibrated by shaking for 48 h in a thermostatically 
controlled water bath at 37±0.1 °C. After 48 h, samples were 
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analyzed at 256 nm for oxcarbazepine. Solubility studies were 
performed in triplicate (n=3). 
Preparation of physical mixtures and solid dispersions 
For oxcarbazepine solid dispersions were prepared by three 
different methods viz. kneading method, melting method and solvent 
evaporation method in three different ratios by using polyvinyl 
pyrrolidone K30 and polyethylene glycol 6000 as hydrophilic 
carriers as shown in table 1. 
Kneading method [9] 
A mixture of oxcarbazepine and polyvinyl pyrrolidone K30 was 
wetted with water and kneaded thoroughly for 30 min, the paste 
formed was dried under vacuum for 24 h. Dried powder was passed 
through sieve no.60. 
Melting method [10] 
Polyethylene glycol 6000 was melted in a beaker on a water bath 
maintained at 50-60 °C. The required amount of oxcarbazepine was 
then added to melted polyethylene glycol 6000 and mixed 
thoroughly for 5 min. The molten mixture was cooled rapidly by 
placing it in an ice bath for about 5 min and solidified. The hardened 
mixture was powdered, sieved through an 80-mesh screen. 
Solvent evaporation method [11] 
Accurately weighed the quantity of polyethylene glycol 6000 was 
dissolved in 10 ml of acetone. To these solutions, accurately weighed 
quantities of oxcarbazepine was added and allowed to dissolve. The 
solution was transferred to a petri dish and the solvent was allowed 
to evaporate at room temperature for 1 h and then was kept in a 
desiccator for 48 h. 
 
Table 1: Ratio of drug and carrier used for the preparation of solid dispersion 
Code Quantity of drug Quantity of carrier Ratio (Drug: carrier) 
SD1 150 mg 150 mg (1:1) 
SD2 150 mg 300 mg (1:2) 
SD3 150 mg 750 mg (1:5) 
 
Evaluation of solid dispersions [8] 
Fourier transforms infrared spectroscopy (FTIR) 
Fourier transform infrared spectra were obtained by potassium 
bromide (KBr) disc method using Shimadzu FTIR-8700 
spectrophotometer (Tokyo, Japan). The scanning range was 40 to 
4000/cm and the resolution was 4/cm. 
Differential scanning calorimetry (DSC) 
Differential scanning calorimetry was performed using DSC (SISI 
Nanothec) on 6.5-10 mg samples of pure oxcarbazepine, 
polyethylene glycol and oxcarbazepine-polyethylene glycol 6000 
solid dispersions. Samples were heated in an open aluminium pan at 
a constant rate of 20 °C/min over a temperature range 20 °C to 350 
°C under nitrogen purge (10 ml/min). 
Powder x-ray diffraction  
The powder x-ray diffraction patterns were determined for 
oxcarbazepine, polyethylene glycol and oxcarbazepine–polyethylene 
glycol 6000 solid dispersions using x-ray diffractometer (Bruker, 
Germany, D8 advance) ceramic x-ray, cu anode, voltage 2.2 KV, 
Detector-lynx eye detector (silicon strip detector technology). The 
scanning rate was 1 °/min over a 2 θ range of 1-50 °C.  
In vitro dissolution 
The in vitro dissolution for the solid dispersions (equivalent to 150 
mg of the oxcarbazepine) was carried out using USP Paddle type II 
apparatus (Paddle method). The dissolution medium used was 1% 
sodium lauryl sulphate [12] 900 ml, maintained at 37±0.5 °C and 
paddles rotated at 75 rpm. 10 ml of sample was withdrawn every 10 
min, filtered through a membrane filter (pore size 0.45 μm) and 
analyzed at 256 nm for oxcarbazepine. Similarly, the pure drug (150 
mg) and the physical mixture were subjected to in vitro drug release 
studies and their release profiles were compared. 
Preparation of oxcarbazepine fast dissolving tablets 
The solid dispersion (SD1) having the maximum solubility and 
dissolution rate was selected for the preparation of fast dissolving 
tablets according to the formula and 150 mg oxcarbazepine 
equivalent was incorporated into each tablet. All the ingredients 
(except magnesium stearate) were mixed homogeneously and co 
ground in a mortar and pestle. Finally, magnesium stearate was 
added and mixed for 5 min and the powder blend was evaluated for 
flow properties such as tapped density, bulk density, Hausner’s ratio, 
compressibility index and angle of repose. The mixed blend of drug 
and excipients was compressed using cadmach 16 station tablet 
punching machine using 10 mm punches to produce flat faced 
tablets weighing 400 mg each for oxcarbazepine as shown in table 2. 
 
Table 2: Formulation of fast dissolving tablets of oxcarbazepine 
S. No. Ingredients (mg) F1 F2 F3 F4 F5 F6 F7 F8 F9 
1 Amount of complex equivalent to 150 
mg of Oxcarbazepine (1:1) 
300 300 300 300 300 300 300 300 300 
2 Mannitol 58 50 46 58 50 46 58 50 46 
3 Ac-di-sol 12 4 0 12 4 0 12 4 0 
4 Sodium starch glycolate 0 24 16 0 24 16 0 24 16 
5 Crosspovidone 8 0 16 8 0 16 8 0 16 
6 Magnesium stearate 4 2 3 2 3 4 3 4 2 
7 Aerosol 2 4 3 4 3 2 3 2 4 
8 Aspartame 16 16 16 16 16 16 16 16 16 
 
Evaluation of prepared tablets 
The tablet hardness [13] and friability [14] were determined using 
monsanto tablet hardness tester and friabilator (Roche), 
respectively. The disintegration time [15] was measured by using 
tablet disintegrator (Electrolab, India). Wetting time [16] was 
determined by well-reported method. A tissue paper was folded 
double and placed in a petri dish (internal diameter 10 cm) 
containing 10 ml of eosin dye solution. The tablet was carefully 
placed on the surface of tissue paper. The time required for the 
tablet to get colored completely red was noted as wetting time. 
Tablets were also evaluated for parameters such as weight variation 
[17], content uniformity [18] and water absorption ratio [19]. 
In vitro release studies of oxcarbazepine tablet 
The release rate of tablets containing a solid dispersion of 
oxcarbazepine (SD1) and marketed formulation (containing 
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equivalent of 150 mg of the oxcarbazepine) (n=6) was determined 
using USP Type II apparatus (Paddle method). The dissolution 
medium used was 900 ml of 1% sodium lauryl sulphate maintained 
at 37±0.5 °C and paddles rotated at 75 rpm. 10 ml of sample was 
withdrawn after every 1 min, filtered through a membrane filter 
(pore size 0.45 μm) and analyzed at 256 nm for oxcarbazepine.  
Mathematical analysis of in vitro data 
The data obtained from in vitro release studies were analyzed by the 
curve fitting method to various models viz., zero, first-order kinetics, 
Higuchi and Korsmeyer-peppas model [20]. In order to evaluate the 
similarity between the optimized formulation and marketed 
formulation, the in vitro dissolution profiles of both were compared [21]. 
In vivo studies 
The bioavailability studies for pure oxcarbazepine, tablets with solid 
dispersion of oxcarbazepine (F4), and marketed formulation 
(Oleptal DTR) were carried out using male wistar rats (200-250 g). 
The animals were maintained in a clean room at a temperature 
between 20-25 °C with 12-hour light and dark cycles and controlled 
relative humidity. The animals were fasted for 12 h prior to the 
commencement of the study as well as during the study and had 
access to water ad libitum. The institutional animal ethical clearance 
(vide letter no. CPCSEA/MRCP/1217/2008/) was obtained before 
conducting the studies. They were divided into four groups (six in each 
group); group I served as a control group, whereas other three groups 
were treated with pure drug oxcarbazepine suspended in 1% solution 
of carboxy methyl cellulose [19], marketed formulation and tablets 
with solid dispersion of oxcarbazepine (F4) respectively. Tablets with 
a dose of 30 mg/kg body weight of rats were administered by 
dispersing in distilled water through oral feeding pipe [22]. 
Blood samples were collected from the lateral tail vein [23] of rats at 
10, 20, 30 min, followed by 1, 1.5, 2, 3, 4, 6 and 24 h after 
administration. The blood samples were centrifuged at 3000 rpm for 
10 min and 100 µl of plasma samples were stored at-20 °C until 
analysis. The plasma concentration of the drug was determined by 
high performance liquid chromatography. The high performance 
liquid chromatography system consisted of a system controller (M-
721), a data module (M-730), a solvent delivery pump (M-501), an 
autosampler (WISP-712) and a variable wavelength U. V. detector 
(M-481) using a symmetry C18 stainless steel column (150 × 3.9 mm 
i.d., 5 µm) and 0.01 M potassium phosphate–acetonitrile–methanol 
(70:20:10% v/v/v) (PH 6.7) using a flow rate of 1.3 ml/min as a 
mobile phase at 214 nm.  
The results obtained were analyzed for various non-compartmental 
pharmacokinetic parameters using pk functions. Furthermore, the 
pharmacokinetic data were analyzed statistically [24] by one way 
ANOVA followed by Dunnett post hoc test for multiple comparisons. 
Stability studies 
Accelerated stability studies [25] were carried out for optimized 
formulation (F4) as per ICH guidelines. The optimized formulation 
(F4) was sealed in high density polyethylene bottles and stored at 
40±2 °C/75±5 % relative humidity for 6 mo period. Samples were 
withdrawn at the end of three and six mo and evaluated for in vitro 
drug release pattern, hardness and disintegration time. A paired test 
was applied to tablet dissolution initially and after 6 mo results, in 
order to study the effect of storage.  
RESULTS AND DISCUSSION 
Screening of appropriate carrier for oxcarbazepine solid 
dispersion 
Preliminary solubility analysis was carried out to screen the most 
appropriate carriers wherein polyethylene glycol 4000 and 
polyethylene glycol 6000 were used. The results of the phase 
solubility revealed that both polyethylene glycol 4000 and 
polyethylene glycol 6000 enhance the solubility of oxcarbazepine 
significantly. More pronounced and linear results were obtained for 
solubility analysis from polyethylene glycol 6000 and hence it was 
selected as the carrier for the preparation of solid dispersion of 
oxcarbazepine (fig. 1). 
 
 
Fig. 1: Effect of carriers on the solubility of pure oxcarbazepine, 
mean±SD, n=3 
 
Preparation of solid dispersions 
For oxcarbazepine solid dispersions were prepared by three 
different methods viz. kneading method, melting method and solvent 
evaporation method in three different ratios by using polyvinyl 
pyrrolidone K30 for the kneading method and polyethylene glycol 
6000 as hydrophilic carriers for both melting method and solvent 
evaporation method as shown in table 1. 
The physical observation of solid dispersion prepared by both 
melting method and solvent evaporation method indicated that the 
solid dispersion prepared by melting method and solvent 
evaporation was free flowing in nature, whereas the solid dispersion 
prepared by kneading method was sticky in nature and not used for 
further studies and hence, it was concluded that polyethylene glycol 
was the most suitable polymeric carrier. 
 
 
Fig. 2: FTIR curves melting method a) Pure drug oxcarbazepine b) Polyethylene glycol c) SD 1:1 d) SD 1:2 e) SD 1:5 
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Fig. 3: FTIR curves solvent evaporation method a) Pure drug oxcarbazepine b) Polyethylene glycol c) SD 1:1 d) SD 1:2 e) SD 1:5 
 
Evaluation of solid dispersions 
Fourier transform infrared spectroscopy 
The spectrum of the oxcarbazepine is characterized by the presence of 
a strong absorption band at 3344 cm-1 and 3466 cm-1 which are all 
indicative of amines (-NH-group). The carbonyl-stretching mode 
appears as a very strong doublet at 1685 cm-1 and 1654 cm-1 (C=O 
stretching) and at 1563 cm-1 and 1481 cm-1 which were indicative of 
the presence of aromatic rings. All the characteristic peaks of the drug 
and polymer appear in the spectra of solid dispersion of oxcarbazepine 
(prepared by melting and solvent evaporation method) indicating no 
interaction between the drug and carrier. (fig. 2 and 3). 
Differential scanning calorimetry 
The thermogram of solid dispersions showed a shift in the endothermic 
peaks of both drugs as well as polymer. This data suggests the complete 
amorphization of drug in the polymer which may be helpful in increasing 
the solubility of pure drug in the formulation (fig. 4 and 5). 
 
 
Fig. 4: DSC Thermogram melting method a) Pure drug oxcarbazepine b) Polyethylene glycol c) SD 1:1 d) SD 1:2 e) SD 1:5 
 
 
Fig. 5: DSC Thermogram solvent evaporation method a) Pure drug oxcarbazepine b) Polyethylene glycol c) SD 1:1 d) SD 1:2 e) SD 1:5 
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Fig. 6: PXRD melting method a) Pure drug oxcarbazepine b) Polyethylene glycol c) SD 1:1 d) SD 1:2 e) SD 1:5 
 
 
Fig. 7: PXRD Solvent evaporation method a) Pure drug oxcarbazepine b) Polyethylene glycol c) SD 1:1 d) SD 1:2 e) SD 1:5 
 
X-ray powder diffraction 
The diffraction pattern of the solid dispersions was simply the 
superimposition of those of the pure components. In case of solid 
dispersions, there was a reduction in the intensities of the drug peaks 
indicating the formation of amorphous compound (fig. 6 and 7). 
Dissolution rate studies 
The dissolution profiles of pure oxcarbazepine, physical mixture 
and solid dispersions (prepared by melting and solvent 
evaporation method) in (1:1) ratio are shown in (fig. 8). 
Oxcarbazepine has shown the release of 40.03±1.38 % after 1 h 
reflecting its low solubility. Oxcarbazepine when combined with 
polyethylene glycol 6000 in 1:2 or 1:5 ratio did not give a 
satisfactory drug release. It was also observed that the release 
profile of solid dispersion was dependent on the method of 
preparation. The dissolution from the physical mixture showed an 
improved drug release profile of 50.16±1.79 %, whereas in the 
solid dispersions, 78.94±2.55 % and 96.23±3.05 % for 
formulations (1:1) prepared by solvent evaporation and melting 
method, respectively, were observed. This enhancement of 
dissolution of oxcarbazepine from solid dispersion may be due to 
several factors. The presence of amorphous nature increased 
wettability and dispersibility, and particle size reduction are the 
important factors for dissolution rate enhancement. Moreover, 
other factors such as absence of aggregation and/or re-
agglomeration phenomenon during dissolution and particle size 
reduction could be attributed to the better dissolution profile. 
Based on the drug release profile, the solid dispersion SD1 
containing oxcarbazepine and polyethylene glycol 6000 in 1:1 
ratio prepared by melting method was selected for the formulation 
of fast dissolving tablets. 
 
 
Fig. 8: Drug release profile of oxcarbazepine, physical mixture, 
solid dispersion prepared by solvent evaporation method (SE) 
and melting method (MM), mean±SD, n=3 
 
Preparation and Evaluation of pre compression parameters 
The pre compression characteristics of all the nine formulations of 
oxcarbazepine were evaluated for flow properties such as tapped 
density, bulk density, Hausner’s ratio, compressibility index and 
angle of repose as shown in table 3. 
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Table 3: Powder characteristics of oxcarbazepine 
Formulation Tapped density 
g/cm3 (t) a 
Bulk density g/cm3 (b) a Hausner’s 
Ratio h=t/ba 
Carr’s index 
c= 100 * (1-1/h) a 
Angle of repose (θ) 
tan-1=h/r. a 
F1 0.45±0.02 0.40±0.02 1.13±0.01 12±0.03 29±1 
F2 0.47±0.03 0.41±0.01 1.15±0.03 13±0.02 30±3 
F3 0.47±0.01 0.40±0.02 1.18±0.01 15±0.02 27±2 
F4 0.41±0.02 0.37±0.01 1.11±0.05 10±0.04 28±2 
F5 0.47±0.01 0.42±0.02 1.12±0.01 11±0.05 26±3 
F6 0.44±0.02 0.39±0.01 1.13±0.01 12±0.04 29±2 
F7 0.46±0.02 0.36±0.02 1.28±0.04 22±0.02 32±4 
F8 0.48±0.01 0.32±0.01 1.50±0.01 33±0.01 33±1 
F9 0.49±0.01 0.31±0.01 1.58±0.01 37±0.01 34±1 
amean±SD, n=3 
 
The pre compression characteristics of all the nine formulations of 
oxcarbazepine indicated that the tapped density, bulk density, 
Hausner’s ratio, compressibility index and angle of repose for all the 
formulations was within the acceptable range barring F8 and F9 
which did not give good results.  
Evaluation of post compression parameters 
All the tablet parameters were measured six times and the mean 
reported with standard deviations. The prepared tablets were 
spherical and white in colour. The mean weight, content uniformity 
and friability of all the 9 formulations were within the acceptable 
range. The hardness range for the fast dissolving tablets should be 
between 2-4 kg/cm2 and friability readings should be below 1%. 
Fast dissolving tablets are required to disintegrate within 2 min. The 
wetting time for the tablets is used as an indicator of the ease of 
tablet dissolution in the buccal cavity. Hydrophobicity of the 
compound, as well as the inner composition of the tablet has an 
effect on the wetting time of the tablet as shown in table 4. 
 


















F1 400±0.3 98.21±.31 2.5±0.1 0.84±0.02 16.37±0.5 46.54±1.00 43.49±0.4 
F2 400±0.2 97.26±2.68 2.5±0.1 0.82±0.01 17.28±0.4 50.01±2.11 42.17±0.5 
F3 400±0.1 99.47±1.45 2.5±0.0 0.83±0.03 18.45±0.1 47.66±2.51 43.62±0.5 
F4 400±0.5 96.37±1.76 2.5±0.0 0.84±0.03 16.45±0.4 48.42±.51 44.15±0.3 
F5 400±0.7 96.11±2.55 2.5±0.1 0.85±0.02 16.38±0.6 49.99±.28 43.56±0.4 
F6 400±0.8 95.54±3.01 2.5±0.0 0.88±0.02 16.34±0.4 50.66±2.51 42.91±0.5 
F7 400±0.1 97.36±1.65 2.5±0.1 0.83±0.03 17.63±0.4 48.98±2.43 43.75±0.3 
F8 400±0.6 98.52±1.99 2.5±0.0 0.84±0.04 18.21±0.2 49.96±2.33 44.24±0.5 
F9 400±0.3 99.1±0.1 2.5±0.1 0.85±0.04 16.30±0.2 48.87±2.11 43.62±0.5 
amean±SD, n=3, The post compression parameters of the tablets were also found to be acceptable and satisfactory.  
 
Dissolution studies of prepared formulation 
From the dissolution analysis, it was clear that optimized 
formulation (F4) showed an enhanced dissolution rate as compared 
to pure oxcarbazepine and marketed formulation. The maximum % 
of drug release was observed with the formulation F4 containing ac-
di-sol and crospovidone combination for oxcarbazepine. The 
increase in dissolution from formulation containing ac-di-sol and 
crospovidone may be due to the wetting and solubilizing effect of 
these superdisintegrants which could reduce the interfacial tension 
between oxcarbazepine and the dissolution medium. Percent of drug 
released from optimized formulation and marketed formulation 
have followed similar pattern and they are very close to each other 
in our study. 
  
 
Fig. 9: The drug release profiles of oxcarbazepine pure drug, oxcarbazepine all formulations and marketed formulation, mean±SD, n=3 
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Mathematical analysis of in vitro dissolution of prepared 
formulations 
The first-order plots were found to be fairly linear for optimized 
formulation as indicated by their high regression values. Korsmeyer 
peppas “n” values less than 0.5 for all the formulations suggest that 
the release of oxcarbazepine from fast dissolving tablets followed 
fickian diffusion mechanism.  
In vivo studies for oxcarbazepine 
The linear regression analysis of oxcarbazepine was constructed by 
plotting the peak–area ratio of drug versus analyte concentration in 
spiked plasma samples. The average regression equation and 
correlation coefficients were calculated. r2 = 0.999 for oxcarbazepine 
showed a good linear relationship between the under peak areas 
and the concentrations. The lower limit of quantization was 0.05 
µg/ml for determination of oxcarbazepine in plasma. The limit had 
been sufficient for pharmacokinetic studies of the oxcarbazepine. 
From the pharmacokinetic analysis, it can be concluded that the in vivo 
studies mimic the in vitro results. The average peak plasma 
concentration obtained from the optimized and marketed formulation 
indicated an increase in the extent of absorption (AUC0-t). Optimized 
and marketed formulation showed Cmax values of 135.45±2.63 µg/ml 
and 130.45±2.68 µg/ml respectively. A difference of almost half an 
hour was observed between the Tmax values of pure drug and 
optimized or marketed formulation. (fig. 10), (table 5). 
 
 
Fig. 10: The plasma concentration time graph for pure drug, optimized formulation (F4) and marketed formulation, mean±SD, n=3 
 
Table 5: Pharmacokinetic parameters of pure drug, optimized formulation (F4) and marketed formulation 
Pharmacokinetics parameters Pure drug Optimized formulation Marketed formulation 
Peak plasma concentration Cmax (µg/ml) 50.73±2.45 135.45±2.63 130.45±2.68 
Time to reach peak plasma concentration Tmax (h) 1±0.172 0.5±0.09 0.5±0.072 
Biological half life t ½(h) 2.02±1.5 1.080±1.2 1.03±0.98 
Elimination rate constant  Ke (h-1) 0.3428±0.068 0.6412±0.033 0.6668±0.026 
Area under the curve AUC (Total) (µg/ml h) 120.82±8.4 165.38±7.9 150.51±7.7 
 
ANOVA followed by Dunnett post hoc t3 test for oxcarbazepine 
indicates that optimized formulation and the marketed formulation 
do not show a significant difference, whereas a significant difference 
is observed between optimized formulation and pure drug 
pharmacokinetic profiles. Mean area under the plasma 
concentration-time curve (AUC) for marketed formulation versus 
optimized formulation indicates that optimized formulation has 
similar bioavailability to the marketed formulation (Oleptal®). The 
higher values of pharmacokinetic parameters (AUC0-t, Cmax, Tmax, 
and t1/2) show enhancement in bioavailability of a drug by 
formulating fast dissolving tablets. Thus, it was concluded that the 
optimized formulation is capable of delivering higher plasma 
concentrations of drug within a shorter span of time as compared to 
pure drug, although not much difference was seen between the 
optimized and marketed formulation. 
Stability studies 
Stability studies showed no remarkable changes in the physical 
properties of the tablets as well as no change in drug content and 
release profile. According to T test results F {t stat (-0.0366)<t 
critical (2.3060)} showing negligible effect of storage on the 
formulated tablet dissolution properties. Hence it can be 
conclusively stated that the dissolution studies show compliance 
with the ICH guidelines demonstrating shelf life through curve fitting 
at 95% confidence limit as shown in table 6 and 7. 
 
Table 6: Accelerated stability studies on oxcarbazepine 
Parameters Initiala 3 moa 6 moa 
Wt of tab (mg) 400±0.2 400±0.1 400±0.1 
Hardness (kg/cm2) 2.6±0.1 2.5±0.1 2±0.03 
Friability (%) 0.84±0.03 0.84±0.01 0.84±0.02 
Wetting Time (s) 45±1 46±2 46±2.2 
Content Uniformity (%) 98±0.1 97.9±0.1 97.8±0.1 
Disintegration (s) 16±1 18±1 16±2 
amean±SD, n=3 
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Table 7: In vitro cumulative % drug release at 40±2 °C/75±5% relative humidity for oxcarbazepine 
Time in mins Cumulative percentage drug release 
Initiala After 3 moa After 6 moa 
4 72.64±0.4 72.44±0.5 72.82±0.33 
8 82±0.3 83±0.5 82±0.4 
12 85±0.3 85.5±0.7 85.23±0.5 
16 92.72±0.3 92.62±0.8 93.47±0.4 
20 98.72±0.3 98.62±0.8 98.47±0.4 
amean±SD, n=3 
 
Oxcarbazepine is having low solubility many techniques have been 
tried in the past in order to improve its solubility and dissolution. 
Malke et al. prepared fast dissolving tablets of oxcarbazepine in the 
year 2007 using wet granulation technique and the prepared tablets 
reported a disintegration time of 28±5 secs [12]. According to the 
method developed by the authors in the above text direct 
compression was used for the preparation of fast dissolving tablets 
which is superior to wet granulation technique due to convenience 
in processing and tablets prepared using optimized formulation (F4) 
reported the disintegration time of 16.45±0.4 secs. Moreover, three 
different methods evaluated for the formulation of solid dispersions 
as compared to previously reported work of Kalia et al. in the year 
2009 [26] wherein only one method was used for the preparation of 
solid dispersions. According to previously reported literature by 
Neduri et al. who studied different techniques to enhance the 
dissolution rate of poorly soluble drugs [27] superdisintegrant 
method used in the above text was found to be superior to the other 
methods in improving the dissolution of poorly soluble drugs [28]. 
CONCLUSION 
Therefore, the solid dispersions prepared by melting method using 
polyethylene glycol 6000 as hydrophilic carrier can be successfully 
used for the improvement of dissolution of oxcarbazepine and 
resulted in faster onset of action as indicated by in vivo studies. 
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